Citigroup
PCVX icon

Citigroup’s Vaxcyte PCVX Stock Holding History

Citigroup’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-29,900
Closed -$972K – 6259
2025
Q2 		$972K Buy
+29,900
New +$980K ﹤0.01% 3213
2025
Q1 		– Sell
-12,500
Closed -$1.02M – 5855
2024
Q4 		$1.02M Buy
+12,500
New +$1.24M ﹤0.01% 3350
2023
Q1 		– Sell
-6,200
Closed -$297K – 5767
2022
Q4 		$297K Hold
6,200
– – ﹤0.01% 3513
2022
Q3 		$149K Buy
+6,200
New +$157K ﹤0.01% 3904

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Citigroup's PCVX Position: Q2 2026 in Review

Citigroup increased its Vaxcyte (PCVX) stake by 53% in Q2 2026, buying an estimated $3.83M and bringing the position to 202,673 shares worth $11.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1488.

Citigroup first reported a position in PCVX in Q3 2020 and has held it in 24 quarters since. The position peaked at $31M in Q4 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Citigroup held 202,673 shares of Vaxcyte worth $11.8M as of Q2 2026.
  • Citigroup bought 70,495 Vaxcyte shares in Q2 2026, an estimated $3.83M.
  • Vaxcyte made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1488 holding.
  • Citigroup first reported a position in Vaxcyte in Q3 2020 and has held it in 24 quarters since.
  • Citigroup's Vaxcyte position peaked at $31M in Q4 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.